These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21184580)

  • 1. Screening of human LPHN3 for variants with a potential impact on ADHD susceptibility.
    Domené S; Stanescu H; Wallis D; Tinloy B; Pineda DE; Kleta R; Arcos-Burgos M; Roessler E; Muenke M
    Am J Med Genet B Neuropsychiatr Genet; 2011 Jan; 156B(1):11-8. PubMed ID: 21184580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study.
    Bruxel EM; Salatino-Oliveira A; Akutagava-Martins GC; Tovo-Rodrigues L; Genro JP; Zeni CP; Polanczyk GV; Chazan R; Schmitz M; Arcos-Burgos M; Rohde LA; Hutz MH
    Genes Brain Behav; 2015 Jun; 14(5):419-27. PubMed ID: 25989180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication.
    Arcos-Burgos M; Jain M; Acosta MT; Shively S; Stanescu H; Wallis D; Domené S; Vélez JI; Karkera JD; Balog J; Berg K; Kleta R; Gahl WA; Roessler E; Long R; Lie J; Pineda D; Londoño AC; Palacio JD; Arbelaez A; Lopera F; Elia J; Hakonarson H; Johansson S; Knappskog PM; Haavik J; Ribases M; Cormand B; Bayes M; Casas M; Ramos-Quiroga JA; Hervas A; Maher BS; Faraone SV; Seitz C; Freitag CM; Palmason H; Meyer J; Romanos M; Walitza S; Hemminger U; Warnke A; Romanos J; Renner T; Jacob C; Lesch KP; Swanson J; Vortmeyer A; Bailey-Wilson JE; Castellanos FX; Muenke M
    Mol Psychiatry; 2010 Nov; 15(11):1053-66. PubMed ID: 20157310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further replication of the synergistic interaction between LPHN3 and the NTAD gene cluster on ADHD and its clinical course throughout adulthood.
    Kappel DB; Schuch JB; Rovaris DL; da Silva BS; Cupertino RB; Winkler C; Teche SP; Vitola ES; Karam RG; Rohde LA; Bau CHD; Grevet EH; Mota NR
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):120-127. PubMed ID: 28624582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of LPHN3 to the genetic susceptibility to ADHD in adulthood: a replication study.
    Ribasés M; Ramos-Quiroga JA; Sánchez-Mora C; Bosch R; Richarte V; Palomar G; Gastaminza X; Bielsa A; Arcos-Burgos M; Muenke M; Castellanos FX; Cormand B; Bayés M; Casas M
    Genes Brain Behav; 2011 Mar; 10(2):149-57. PubMed ID: 21040458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Ultraconserved Brain-Specific Enhancer Within ADGRL3 (LPHN3) Underpins Attention-Deficit/Hyperactivity Disorder Susceptibility.
    Martinez AF; Abe Y; Hong S; Molyneux K; Yarnell D; Löhr H; Driever W; Acosta MT; Arcos-Burgos M; Muenke M
    Biol Psychiatry; 2016 Dec; 80(12):943-954. PubMed ID: 27692237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of a latrophilin 3 (LPHN3) risk haplotype on event-related potential measures of cognitive response control in attention-deficit hyperactivity disorder (ADHD).
    Fallgatter AJ; Ehlis AC; Dresler T; Reif A; Jacob CP; Arcos-Burgos M; Muenke M; Lesch KP
    Eur Neuropsychopharmacol; 2013 Jun; 23(6):458-68. PubMed ID: 23245769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cooperative interaction between LPHN3 and 11q doubles the risk for ADHD.
    Jain M; Vélez JI; Acosta MT; Palacio LG; Balog J; Roessler E; Pineda D; Londoño AC; Palacio JD; Arbelaez A; Lopera F; Elia J; Hakonarson H; Seitz C; Freitag CM; Palmason H; Meyer J; Romanos M; Walitza S; Hemminger U; Warnke A; Romanos J; Renner T; Jacob C; Lesch KP; Swanson J; Castellanos FX; Bailey-Wilson JE; Arcos-Burgos M; Muenke M
    Mol Psychiatry; 2012 Jul; 17(7):741-7. PubMed ID: 21606926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LPHN3 gene variations and susceptibility to ADHD in Chinese Han population: a two-stage case-control association study and gene-environment interactions.
    Huang X; Zhang Q; Gu X; Hou Y; Wang M; Chen X; Wu J
    Eur Child Adolesc Psychiatry; 2019 Jun; 28(6):861-873. PubMed ID: 30406846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward a better understanding of ADHD: LPHN3 gene variants and the susceptibility to develop ADHD.
    Arcos-Burgos M; Muenke M
    Atten Defic Hyperact Disord; 2010 Nov; 2(3):139-47. PubMed ID: 21432600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDH13 and LPHN3 Gene Polymorphisms in Attention-Deficit/Hyperactivity Disorder: Their Relation to Clinical Characteristics.
    Özaslan A; Güney E; Ergün MA; Okur İ; Yapar D
    J Mol Neurosci; 2021 Feb; 71(2):394-408. PubMed ID: 32691279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of LPHN3 rs6551665 A/G polymorphism with attention deficit and hyperactivity disorder in Korean children.
    Hwang IW; Lim MH; Kwon HJ; Jin HJ
    Gene; 2015 Jul; 566(1):68-73. PubMed ID: 25871512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LPHN3 and attention-deficit/hyperactivity disorder: interaction with maternal stress during pregnancy.
    Choudhry Z; Sengupta SM; Grizenko N; Fortier ME; Thakur GA; Bellingham J; Joober R
    J Child Psychol Psychiatry; 2012 Aug; 53(8):892-902. PubMed ID: 22486528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refining psychiatric phenotypes for response to treatment: contribution of LPHN3 in ADHD.
    Labbe A; Liu A; Atherton J; Gizenko N; Fortier MÈ; Sengupta SM; Ridha J
    Am J Med Genet B Neuropsychiatr Genet; 2012 Oct; 159B(7):776-85. PubMed ID: 22851411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attention deficit hyperactivity disorder: genetic association study in a cohort of Spanish children.
    Gomez-Sanchez CI; Riveiro-Alvarez R; Soto-Insuga V; Rodrigo M; Tirado-Requero P; Mahillo-Fernandez I; Abad-Santos F; Carballo JJ; Dal-Ré R; Ayuso C
    Behav Brain Funct; 2016 Jan; 12(1):2. PubMed ID: 26746237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convergent selective signaling impairment exposes the pathogenicity of latrophilin-3 missense variants linked to inheritable ADHD susceptibility.
    Moreno-Salinas AL; Holleran BJ; Ojeda-Muñiz EY; Correoso-Braña KG; Ribalta-Mena S; Ovando-Zambrano JC; Leduc R; Boucard AA
    Mol Psychiatry; 2022 May; 27(5):2425-2438. PubMed ID: 35393556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial characterization of mice null for Lphn3, a gene implicated in ADHD and addiction.
    Wallis D; Hill DS; Mendez IA; Abbott LC; Finnell RH; Wellman PJ; Setlow B
    Brain Res; 2012 Jun; 1463():85-92. PubMed ID: 22575564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ADHD-susceptibility gene lphn3.1 modulates dopaminergic neuron formation and locomotor activity during zebrafish development.
    Lange M; Norton W; Coolen M; Chaminade M; Merker S; Proft F; Schmitt A; Vernier P; Lesch KP; Bally-Cuif L
    Mol Psychiatry; 2012 Sep; 17(9):946-54. PubMed ID: 22508465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain structural and functional substrates of ADGRL3 (latrophilin 3) haplotype in attention-deficit/hyperactivity disorder.
    Moreno-Alcázar A; Ramos-Quiroga JA; Ribases M; Sánchez-Mora C; Palomar G; Bosch R; Salavert J; Fortea L; Monté-Rubio GC; Canales-Rodríguez EJ; Milham MP; Castellanos FX; Casas M; Pomarol-Clotet E; Radua J
    Sci Rep; 2021 Jan; 11(1):2373. PubMed ID: 33504901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetics of attention deficit/hyperactivity disorder in adults, a review.
    Franke B; Faraone SV; Asherson P; Buitelaar J; Bau CH; Ramos-Quiroga JA; Mick E; Grevet EH; Johansson S; Haavik J; Lesch KP; Cormand B; Reif A;
    Mol Psychiatry; 2012 Oct; 17(10):960-87. PubMed ID: 22105624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.